Misako Nagasaka

Title(s)Associate Clinical Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024 Apr; 25(4):439-454. Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA. PMID: 38547891.
      View in: PubMed   Mentions:    Fields:    Translation:CTClinical Trials
    2. Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage? J Thorac Oncol. 2024 Apr; 19(4):525-527. Lee JB, Nagasaka M. PMID: 38582542.
      View in: PubMed   Mentions:
    3. Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC. J Thorac Oncol. 2024 Mar; 19(3):380-384. Chen LN, Lee ATM, Nagasaka M, Ou SI. PMID: 38453326.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer. Cancer Res. 2024 Feb 22. Yamamoto T, Hayashida T, Masugi Y, Oshikawa K, Hayakawa N, Itoh M, Nishime C, Suzuki M, Nagayama A, Kawai Y, Hishiki T, Matsuura T, Naito Y, Kubo A, Yamamoto A, Yoshioka Y, Kurahori T, Nagasaka M, Takizawa M, Takano N, Kawakami K, Sakamoto M, Wakui M, Yamamoto T, Kitagawa Y, Kabe Y, Horisawa K, Suzuki A, Matsumoto M, Suematsu M. PMID: 38383964.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    5. Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data. Expert Opin Investig Drugs. 2024 Feb; 33(2):79-84. Nagasaka M, Brazel D, Ou SI. PMID: 38224083.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact. Lung Cancer (Auckl). 2024; 15:1-8. Arter ZL, Nagasaka M. PMID: 38298470; PMCID: PMC10825580.
      View in: PubMed   Mentions:
    7. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jan 24. Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. PMID: 38278303.
      View in: PubMed   Mentions:    Fields:    
    8. HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes. Clin Lung Cancer. 2024 Jan 18. Waliany S, Neal JW, Engel-Nitz N, Lam C, Lin F, Park L, Le L, Nagasaka M. PMID: 38403548.
      View in: PubMed   Mentions:    Fields:    
    9. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024 Jan 11; 390(2):118-131. Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC, TRIDENT-1 Investigators. PMID: 38197815.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    10. Oncogenic fusions: Targeting NTRK. Crit Rev Oncol Hematol. 2024 Feb; 194:104234. Hagopian G, Nagasaka M. PMID: 38122917.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? Lung Cancer (Auckl). 2023; 14:101-109. Nagasaka M, Ou SI. PMID: 38111829; PMCID: PMC10725831.
      View in: PubMed   Mentions:
    12. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]). J Thorac Oncol. 2023 Dec 07. Ou SI, Hagopian GG, Zhang SS, Nagasaka M. PMID: 38070596.
      View in: PubMed   Mentions:    Fields:    
    13. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers. Mol Cancer Ther. 2023 Dec 01; 22(12):1422-1433. Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura SF, Mzannar Y, Azar I, Beal EW, Tobon ME, Kim SH, Beydoun R, Baloglu E, Senapedis W, El-Rayes BF, Philip PA, Mohammad RM, Shields AF, Al Hallak MN, Azmi AS. PMID: 37703579; PMCID: PMC10690049.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab. Allergy Asthma Clin Immunol. 2023 Oct 28; 19(1):93. Lopez M, Hagopian G, Doan L, Lee BJ, Rojek NW, Smith J, Ou SI, Demirdag YY, Nagasaka M. PMID: 37898814; PMCID: PMC10612162.
      View in: PubMed   Mentions:
    15. The development of amivantamab for the treatment of non-small cell lung cancer. Respir Res. 2023 Oct 25; 24(1):256. Brazel D, Nagasaka M. PMID: 37880647; PMCID: PMC10601226.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing. BMC Cancer. 2023 Oct 18; 23(1):1000. Nagasaka M, Zhang SS, Baca Y, Xiu J, Nieva J, Vanderwalde A, Swensen JJ, Spetzler D, Korn WM, Raez LE, Liu SV, Ou SI. PMID: 37853341; PMCID: PMC10585918.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Nat Med. 2023 10; 29(10):2577-2585. Cho BC, Kim DW, Spira AI, Gomez JE, Haura EB, Kim SW, Sanborn RE, Cho EK, Lee KH, Minchom A, Lee JS, Han JY, Nagasaka M, Sabari JK, Ou SI, Lorenzini P, Bauml JM, Curtin JC, Roshak A, Gao G, Xie J, Thayu M, Knoblauch RE, Park K. PMID: 37710001; PMCID: PMC10579096.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    18. Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer. Front Oncol. 2023; 13:1215524. Hsu R, Chen D, Xia B, Feldman R, Cozen W, Raez LE, Borghaei H, Kim C, Nagasaka M, Mamdani H, Vanderwalde AM, Lopes G, Socinski MA, Wozniak AJ, Spira AI, Liu SV, Nieva JJ. PMID: 37700839; PMCID: PMC10494442.
      View in: PubMed   Mentions:
    19. Neoadjuvant therapy in non-small cell lung cancer. Crit Rev Oncol Hematol. 2023 Oct; 190:104080. Grant C, Hagopian G, Nagasaka M. PMID: 37532102.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. Transl Oncol. 2023 Oct; 36:101744. Nagasaka M, Brazel D, Baca Y, Xiu J, Al-Hallak MN, Kim C, Nieva J, Swensen JJ, Spetzler D, Korn WM, Socinski MA, Raez LE, Halmos B, Ou SI. PMID: 37516008; PMCID: PMC10410168.
      View in: PubMed   Mentions: 1  
    21. Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations. Cancer Manag Res. 2023; 15:627-634. Ahn J, Nagasaka M. PMID: 37457376; PMCID: PMC10349595.
      View in: PubMed   Mentions:
    22. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review. Cancers (Basel). 2023 Jul 10; 15(14). Hsu R, Benjamin DJ, Nagasaka M. PMID: 37509224; PMCID: PMC10377299.
      View in: PubMed   Mentions: 1  
    23. Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy. Am J Hosp Palliat Care. 2023 Jul 05; 10499091231187999. Harris JP, Ku E, Harada G, Hsu S, Chiao E, Rao P, Healy E, Nagasaka M, Humphreys J, Hoyt MA. PMID: 37406195; PMCID: PMC10772523.
      View in: PubMed   Mentions:    Fields:    
    24. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Crit Rev Oncol Hematol. 2023 Jul; 187:104019. Ou SI, Lee ATM, Nagasaka M. PMID: 37187318.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    25. Proteolysis targeting chimeras in non-small cell lung cancer. Cancer Treat Rev. 2023 Jun; 117:102561. Hagopian G, Grant C, Nagasaka M. PMID: 37178629.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC. Lung Cancer (Auckl). 2023; 14:41-46. Lee ATM, Nagasaka M. PMID: 37138950; PMCID: PMC10150033.
      View in: PubMed   Mentions: 2  
    27. CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code. Lung Cancer (Auckl). 2023; 14:27-30. Zhang SS, Lee A, Nagasaka M. PMID: 37101895; PMCID: PMC10123019.
      View in: PubMed   Mentions: 2  
    28. Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM). Clin Lung Cancer. 2023 09; 24(6):563-567. Wozniak AJ, Schneider B, Kalemkerian GP, Daly B, Chen W, Ventimiglia J, Nagasaka M, Zauderer MG. PMID: 37301693.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    29. Penetrating the central nervous system sanctuary of KRAS, a target once thought "undruggable". Transl Lung Cancer Res. 2023 Apr 28; 12(4):665-668. Nagasaka M, Azmi AS. PMID: 37197620; PMCID: PMC10183396.
      View in: PubMed   Mentions:
    30. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers. bioRxiv. 2023 Mar 27. Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura S, Mzannar Y, Azar I, Beal E, Tobon M, Kim S, Beydoun R, Baloglu E, Senapedis W, El-Rayes B, Philip PA, Mohammad RM, Shields AF, Al-Hallak MN, Azmi AS. PMID: 37034616; PMCID: PMC10081231.
      View in: PubMed   Mentions:
    31. TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors. Future Oncol. 2023 Jan; 19(2):123-135. Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, Felip E, Pérol M, Besse B, Nieva J, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI. PMID: 36877099.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    32. Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2023 06; 18(6):698-717. Triphuridet N, Zhang SS, Nagasaka M, Gao Y, Zhao JJ, Syn NL, Hanaoka T, Ou SI, Shum E. PMID: 36775191.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    33. Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer (Auckl). 2023; 14:1-9. Brazel D, Ou SI, Nagasaka M. PMID: 36636263; PMCID: PMC9831070.
      View in: PubMed   Mentions: 6  
    34. Neptune, the Next Pluto?-Durvalumab and Tremelimumab Face Challenges in Entering the NSCLC Space. J Thorac Oncol. 2023 01; 18(1):29-30. Ahn JY, Nagasaka M. PMID: 36543434.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    35. In Response to Dr. Steven Sorscher. JTO Clin Res Rep. 2023 Jan; 4(1):100453. Zhang SS, Schrock AB, Nagasaka M, Ou SI. PMID: 36654883; PMCID: PMC9841026.
      View in: PubMed   Mentions:
    36. Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer. JTO Clin Res Rep. 2023 Feb; 4(2):100452. Anwar K, Nguyen L, Nagasaka M, Ou SI, Chan A. PMID: 36568522; PMCID: PMC9759297.
      View in: PubMed   Mentions: 5  
    37. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022 Dec 09; 6(1):91. Lee JK, Sivakumar S, Schrock AB, Madison R, Fabrizio D, Gjoerup O, Ross JS, Frampton GM, Napalkov P, Montesion M, Schutzman JL, Ye X, Hegde PS, Nagasaka M, Oxnard GR, Sokol ES, Ou SI, Shi Z. PMID: 36494601.
      View in: PubMed   Mentions: 10  
    38. CROWN 2022 Second Interim Updates: When Will Be the Coronation of Lorlatinib? J Thorac Oncol. 2022 Nov 29. Nagasaka M, Ou SI. PMID: 36460598.
      View in: PubMed   Mentions: 2     Fields:    
    39. The Utility of Automated ASPECTS in Acute Ischemic Stroke for Intravenous Recombinant Tissue Plasminogen Activator (IV-rtPA) Therapy. Neurol Int. 2022 Nov 21; 14(4):981-990. Shibata S, Sakurai K, Tachikawa K, Ko R, Hino S, Fukano T, Isahaya K, Haraguchi T, Yamauchi J, Tanabe K, Nagasaka M, Hagiwara Y, Shimizu T, Akiyama H, Kobayashi Y, Hasegawa Y, Yamano Y. PMID: 36412699.
      View in: PubMed   Mentions: 1  
    40. A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib. Lung Cancer (Auckl). 2022; 13:75-80. Brazel D, Arter Z, Nagasaka M. PMID: 36387582; PMCID: PMC9662012.
      View in: PubMed   Mentions: 2  
    41. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs. 2022 Nov; 36(6):717-729. Brazel D, Kroening G, Nagasaka M. PMID: 36255589; PMCID: PMC9649507.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    42. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 03; 165(3):828-839.e5. Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. PMID: 36369159; PMCID: PMC10288861.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    43. Validation of deep learning-based computer-aided detection software use for interpretation of pulmonary abnormalities on chest radiographs and examination of factors that influence readers' performance and final diagnosis. Jpn J Radiol. 2023 Jan; 41(1):38-44. Toda N, Hashimoto M, Iwabuchi Y, Nagasaka M, Takeshita R, Yamada M, Yamada Y, Jinzaki M. PMID: 36121622.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    44. Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)? J Clin Oncol. 2023 02 01; 41(4):742-744. Benjamin DJ, Nagasaka M. PMID: 36095291.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    45. Potential role of HTLV-1 Tax-specific cytotoxic t lymphocytes expressing a unique t-cell receptor to promote inflammation of the central nervous system in myelopathy associated with HTLV-1. Front Immunol. 2022; 13:993025. Tanaka Y, Sato T, Yagishita N, Yamauchi J, Araya N, Aratani S, Takahashi K, Kunitomo Y, Nagasaka M, Kanda Y, Uchimaru K, Morio T, Yamano Y. PMID: 36081501; PMCID: PMC9446235.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    46. Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 08 15; 28(16):3464-3472. Leddon JL, Gulati S, Haque S, Allen C, Palackdharry S, Mathews M, Kurtzweil N, Riaz MK, Takiar V, Nagasaka M, Patil Y, Zender C, Tang A, Cervenka B, McGrath J, Korn WM, Hinrichs BH, Jandarov R, Harun N, Sukari A, Wise-Draper TM. PMID: 35653116; PMCID: PMC9378458.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    47. A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature. JTO Clin Res Rep. 2022 Sep; 3(9):100387. Zhang SS, Lee JK, Tukachinsky H, Schrock AB, Nagasaka M, Ou SI. PMID: 36061833; PMCID: PMC9429789.
      View in: PubMed   Mentions: 1  
    48. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clin Res Rep. 2022 Sep; 3(9):100381. Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, Ma PC, Nagasaka M, Reckamp KL, Abraham J, Uprety D, Wang F, Xiu J, Zhang J, Cheng H, Halmos B. PMID: 36082279; PMCID: PMC9445394.
      View in: PubMed   Mentions: 5  
    49. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review. Drugs. 2022 Jun; 82(9):979-987. Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. PMID: 35759121; PMCID: PMC9276583.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    50. Clinical progress of KRAS-targeted therapies: what next? Future Med Chem. 2022 08; 14(15):1107-1110. Nagasaka M, Azmi AS. PMID: 35758004.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    51. African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer. Head Neck. 2022 10; 44(10):2069-2076. Shao YF, Kim S, Cramer JD, Farhat D, Hotaling J, Raza SN, Yoo G, Lin HS, Kim H, Sukari A, Nagasaka M. PMID: 35713967; PMCID: PMC9543059.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    52. The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. Front Oncol. 2022; 12:859892. Liu SV, Nagasaka M, Stefaniak V, Gruver K, Lin Y, Ferry D, Socinski MA, Zhang L. PMID: 35756655; PMCID: PMC9226396.
      View in: PubMed   Mentions:
    53. Preface. Cancer Metastasis Rev. 2022 06; 41(2):245-246. Nagasaka M, Chen G. PMID: 35725839.
      View in: PubMed   Mentions:    Fields:    
    54. Correction to: Connecting the human microbiome and pancreatic cancer. Cancer Metastasis Rev. 2022 Jun; 41(2):333. Sexton RE, Uddin MH, Bannoura S, Khan HY, Mzannar Y, Li Y, Aboukameel A, Al-Hallak MN, Al-Share B, Mohamed A, Nagasaka M, El-Rayes B, Azmi AS. PMID: 35536453; PMCID: PMC9486138.
      View in: PubMed   Mentions:    Fields:    
    55. Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC. Lung Cancer (Auckl). 2022; 13:47-52. Brazel D, Nagasaka M. PMID: 35615402; PMCID: PMC9126226.
      View in: PubMed   Mentions:
    56. Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. Lung Cancer (Auckl). 2022; 13:33-45. Brazel D, Zhang S, Nagasaka M. PMID: 35592355; PMCID: PMC9113513.
      View in: PubMed   Mentions: 6  
    57. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029. Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, Menke van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF. PMID: 35165101; PMCID: PMC9365353.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    58. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers. Cancer Res Commun. 2022 05; 2(5):342-352. Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, Mohammad RM, Shields AF, Azmi AS. PMID: 35573474; PMCID: PMC9105196.
      View in: PubMed   Mentions: 6  Translation:HumansAnimals
    59. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Med. 2022 07; 11(13):2541-2549. Wang H, Li ZW, Ou Q, Wu X, Nagasaka M, Shao Y, Ou SI, Yang Y. PMID: 35506567; PMCID: PMC9249987.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    60. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2022 May; 106:102393. Abuhelwa Z, Alloghbi A, Nagasaka M. PMID: 35472631.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    61. Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy. Front Med (Lausanne). 2022; 9:879379. Kimura M, Yamauchi J, Sato T, Yagishita N, Araya N, Aratani S, Tanabe K, Horibe E, Watanabe T, Coler-Reilly A, Nagasaka M, Akasu Y, Kaburagi K, Kikuchi T, Shibata S, Matsumoto H, Koseki A, Inoue S, Takata A, Yamano Y. PMID: 35479934; PMCID: PMC9036434.
      View in: PubMed   Mentions:
    62. Connecting the Human Microbiome and Pancreatic Cancer. Cancer Metastasis Rev. 2022 06; 41(2):317-331. Sexton RE, Uddin MH, Bannoura S, Khan HY, Mzannar Y, Li Y, Aboukameel A, Al-Hallak MN, Al-Share B, Mohamed A, Nagasaka M, El-Rayes B, Azmi AS. PMID: 35366155; PMCID: PMC8976105.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    63. Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer. Future Oncol. 2022 May; 18(16):1963-1977. Nagasaka M, Molife C, Cui ZL, Stefaniak V, Li X, Kim S, Lee HY, Beyrer J, Blumenschein G. PMID: 35354280.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    64. ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression? Lung Cancer (Auckl). 2022; 13:13-21. Nagasaka M, Ou SI. PMID: 35378922; PMCID: PMC8976558.
      View in: PubMed   Mentions: 1  
    65. Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations. Clin Lung Cancer. 2022 06; 23(4):333-344. Harris JP, Fujimoto DK, Nagasaka M, Ku E, Harada G, Keshava H, Mahtabifard A, Longoria J, Patel N, Seyedin S, Simon A, Chen A. PMID: 35256282.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy. J Thorac Oncol. 2022 02; 17(2):182-185. Nagasaka M, Ou SI. PMID: 35074224.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    67. Clinical utility of the Bosniak classification version 2019: Diagnostic value of adding magnetic resonance imaging to computed tomography examination. Eur J Radiol. 2022 Mar; 148:110163. Arita Y, Yoshida S, Kwee TC, Edo H, Kufukihara R, Shigeta K, Nagasaka M, Takeshita R, Okamura H, Ueda R, Ishii R, Okuda S, Fujii Y. PMID: 35066340.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    68. Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P). Viruses. 2022 01 12; 14(1). Yamauchi J, Tanabe K, Sato T, Nakagawa M, Matsuura E, Tsuboi Y, Tamaki K, Sakima H, Ishihara S, Ohta Y, Matsumoto N, Kono K, Yagishita N, Araya N, Takahashi K, Kunitomo Y, Nagasaka M, Coler-Reilly A, Hasegawa Y, Araujo A, Jacobson S, Grassi MFR, Galvão-Castro B, Bland M, Taylor GP, Martin F, Yamano Y. PMID: 35062340; PMCID: PMC8780460.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    69. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. Trends Cancer. 2022 03; 8(3):242-258. Nagasaka M, Ou SI. PMID: 34996744.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    70. Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. Lung Cancer. 2022 02; 164:52-55. Nagasaka M, Balmanoukian AS, Madison R, Zhang SS, Klempner SJ, Ou SI. PMID: 35032819.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    71. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021 Dec 07; 12(25):2449-2458. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ. PMID: 34917263; PMCID: PMC8664394.
      View in: PubMed   Mentions: 4     Fields:    
    72. Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2021; 12:133-138. Brazel D, Nagasaka M. PMID: 34880698; PMCID: PMC8648093.
      View in: PubMed   Mentions: 13  
    73. Incidence of Second Primary Lung Cancer After Low-Dose Computed Tomography vs Chest Radiography Screening in Survivors of Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2021 12 01; 147(12):1071-1078. Cramer JD, Grauer J, Sukari A, Nagasaka M. PMID: 34709369; PMCID: PMC8554690.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    74. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat Rev. 2021 Dec; 101:102309. Nagasaka M, Potugari B, Nguyen A, Sukari A, Azmi AS, Ou SI. PMID: 34715449.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    75. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. Clin Lung Cancer. 2022 01; 23(1):52-59. Nagasaka M, Singh V, Baca Y, Sukari A, Kim C, Mamdani H, Spira AI, Uprety D, Bepler G, Kim ES, Raez LE, Pai SG, Ikpeazu C, Oberley M, Feldman R, Xiu J, Korn WM, Wozniak AJ, Borghaei H, Liu SV. PMID: 34801409.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    76. Immune checkpoint inhibitor-induced pneumonitis: Incidence, clinical characteristics, and outcomes. Hematol Oncol Stem Cell Ther. 2021 Oct 18. Banavasi H, Kim S, Alkassis S, Daoud A, Laktineh A, Nagasaka M, Sukari A, Soubani AO. PMID: 34688626.
      View in: PubMed   Mentions: 4     Fields:    
    77. Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2021; 12:115-122. Zhang SS, Nagasaka M. PMID: 34675734; PMCID: PMC8504654.
      View in: PubMed   Mentions: 15  
    78. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2021; 12:103-114. Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, Sukari A, Nagasaka M. PMID: 34675733; PMCID: PMC8507417.
      View in: PubMed   Mentions: 4  
    79. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 01 20; 386(3):241-251. Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA, DESTINY-Lung01 Trial Investigators. PMID: 34534430; PMCID: PMC9066448.
      View in: PubMed   Mentions: 211     Fields:    Translation:HumansCTClinical Trials
    80. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021 12; 20(12):2577-2584. Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. PMID: 34518295.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    81. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev. 2021 09; 40(3):819-835. Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. PMID: 34499267; PMCID: PMC8556325.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    82. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 2021 10; 160:92-98. Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS. PMID: 34482103; PMCID: PMC8853639.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    83. Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? Transl Oncol. 2021 Nov; 14(11):101191. Ou SI, Nagasaka M, Brazel D, Hou Y, Zhu VW. PMID: 34365220; PMCID: PMC8353359.
      View in: PubMed   Mentions: 17  
    84. Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis. Head Neck. 2021 11; 43(11):3681-3696. Quan DL, Sukari A, Nagasaka M, Kim H, Cramer JD. PMID: 34323332.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    85. p16 positive oropharyngeal small cell cancer: A case report. Oral Oncol. 2021 10; 121:105391. Al Masalmeh N, Kukreja G, Zaiem F, Raza SN, Kim H, Nagasaka M, Sukari A. PMID: 34187735.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    86. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer. 2021 08; 158:126-136. Zhang SS, Nagasaka M, Zhu VW, Ou SI. PMID: 34175504.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    87. Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. J Clin Oncol. 2021 09 01; 39(25):2791-2802. Drilon A, Duruisseaux M, Han JY, Ito M, Falcon C, Yang SR, Murciano-Goroff YR, Chen H, Okada M, Molina MA, Wislez M, Brun P, Dupont C, Branden E, Rossi G, Schrock A, Ali S, Gounant V, Magne F, Blum TG, Schram AM, Monnet I, Shih JY, Sabari J, Pérol M, Zhu VW, Nagasaka M, Doebele R, Camidge DR, Arcila M, Ou SI, Moro-Sibilot D, Rosell R, Muscarella LA, Liu SV, Cadranel J. PMID: 34077268; PMCID: PMC8407651.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    88. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021 06 01; 20(1):82. Nagasaka M, Uddin MH, Al-Hallak MN, Rahman S, Balasubramanian S, Sukari A, Azmi AS. PMID: 34074295; PMCID: PMC8170728.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    89. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer. 2021 07; 157:147-155. Zhu VW, Zhao JJ, Gao Y, Syn NL, Zhang SS, Ou SI, Bauer KA, Nagasaka M. PMID: 34049720.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    90. Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer. Clin Lung Cancer. 2021 11; 22(6):e842-e850. Fisher A, Kim S, Farhat D, Belzer K, Milczuk M, French C, Mamdani H, Sukari A, Baciewicz F, Schwartz AG, Wozniak A, Nagasaka M. PMID: 34053862; PMCID: PMC8536802.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    91. Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. J Thorac Oncol. 2021 04; 16(4):532-536. Nagasaka M, Ou SI. PMID: 33781444.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    92. Utility of transoral motion-mode ultrasonography to detect tongue fasciculation in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2021 06; 63(6):909-913. Hagiwara Y, Shimizu T, Yanagisawa T, Akasu Y, Kaburagi K, Kikuchi T, Shibata S, Matsumoto H, Soga K, Tsuchihashi Y, Nagasaka M, Sasaki N, Maki F, Shiraishi M, Akiyama H, Hasegawa Y, Yamano Y. PMID: 33675079.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    93. Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. Sci Rep. 2021 03 11; 11(1):5639. Elliott A, Saul M, Zeng J, Marshall JL, Kim ES, Nagasaka M, Lenz HJ, Schwartzberg L, Spetzler D, Abraham J, Xiu J, Stafford P, Michael Korn W. PMID: 33707526; PMCID: PMC7952699.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    94. Forget me not - Incorporating standard chemotherapy in an exciting era of clinical trials. Oral Oncol. 2021 05; 116:105160. Nguyen A, Nagasaka M. PMID: 33487535.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    95. Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. JTO Clin Res Rep. 2021 Feb; 2(2):100132. Ou SI, Xiu J, Nagasaka M, Xia B, Zhang SS, Zhang Q, Swensen JJ, Spetzler D, Korn WM, Zhu VW, Liu SV. PMID: 34589990; PMCID: PMC8474258.
      View in: PubMed   Mentions: 7  
    96. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2021 05; 16(5):740-763. Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou SI. PMID: 33338652.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    97. How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2020 Dec; 9(6):2521-2534. Xia B, Nagasaka M, Zhu VW, Ou SI, Soo RA. PMID: 33489815; PMCID: PMC7815371.
      View in: PubMed   Mentions: 7  
    98. STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib. JTO Clin Res Rep. 2021 Feb; 2(2):100125. Nagasaka M, Sarvadevabatla N, Iwata S, Ge Y, Sukari A, Klosowski C, Yanagihara R. PMID: 34589985; PMCID: PMC8474477.
      View in: PubMed   Mentions: 7  
    99. A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. JTO Clin Res Rep. 2021 Jan; 2(1):100116. Zhu VW, Nagasaka M, Madison R, Schrock AB, Cui J, Ou SI. PMID: 34589977; PMCID: PMC8474455.
      View in: PubMed   Mentions: 11  
    100. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy. Clin Lung Cancer. 2021 01; 22(1):e51-e53. Nagasaka M, Fisher A, Chowdhury T, Ge Y, Sukari A. PMID: 32893122.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet J Rare Dis. 2020 07 03; 15(1):175. Yamakawa N, Yagishita N, Matsuo T, Yamauchi J, Ueno T, Inoue E, Takata A, Nagasaka M, Araya N, Hasegawa D, Coler-Reilly A, Tsutsumi S, Sato T, Araujo A, Casseb J, Gotuzzo E, Jacobson S, Martin F, Puccioni-Sohler M, Taylor GP, Yamano Y, Japan Clinical Research Group on HAM/TSP. PMID: 32620176; PMCID: PMC7333329.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    102. Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations. Mol Oncol. 2020 08; 14(8):1731-1739. Fan Y, Qiu J, Yu R, Cao R, Chen X, Ou Q, Wu X, Shao YW, Nagasaka M, Zhang J, Ou SI. PMID: 32478891; PMCID: PMC7400783.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    103. Is NRG2α Fusion a "Doppelgänger" to NRG1α/β Fusions in Oncology? J Thorac Oncol. 2020 06; 15(6):878-880. Nagasaka M, Ou SI. PMID: 32471560.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    104. Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis. Proc Natl Acad Sci U S A. 2020 05 26; 117(21):11685-11691. Nagasaka M, Yamagishi M, Yagishita N, Araya N, Kobayashi S, Makiyama J, Kubokawa M, Yamauchi J, Hasegawa D, Coler-Reilly ALG, Tsutsumi S, Uemura Y, Arai A, Takata A, Inoue E, Hasegawa Y, Watanabe T, Suzuki Y, Uchimaru K, Sato T, Yamano Y. PMID: 32393644; PMCID: PMC7260950.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    105. A user's guide to lorlatinib. Crit Rev Oncol Hematol. 2020 Jul; 151:102969. Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou SI. PMID: 32416346.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    106. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series). Oral Oncol. 2020 10; 109:104744. Sukari A, Kukreja G, Nagasaka M, Shukairy MK, Yoo G, Lin HS, Hotaling J, Kim H. PMID: 32402656.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    107. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. J Thorac Oncol. 2020 09; 15(9):1484-1496. Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, Ang YL, Ock CY, Tchekmedyian N, Ou SI, Syn NL, Reungwetwattana T, Lin CC, Soo RA. PMID: 32360579.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    108. A Catalog of 5' Fusion Partners in ROS1-Positive NSCLC Circa 2020. JTO Clin Res Rep. 2020 Sep; 1(3):100048. Ou SI, Nagasaka M. PMID: 34589944; PMCID: PMC8474457.
      View in: PubMed   Mentions: 11  
    109. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020 07; 145:186-194. Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, Xia B, Zhu VW, Nagasaka M, Yang Y, Li Y, Qiu W, Ying J, Ou SI, Wang Y. PMID: 32336530.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    110. Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clin Res Rep. 2020 Mar; 1(1):100015. Ou SI, Zhu VW, Nagasaka M. PMID: 34589917; PMCID: PMC8474466.
      View in: PubMed   Mentions: 52  
    111. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat Rev. 2020 Mar; 84:101974. Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. PMID: 32014824; PMCID: PMC7041424.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    112. Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. Lung Cancer (Auckl). 2020; 11:13-18. Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI. PMID: 32021525; PMCID: PMC6970251.
      View in: PubMed   Mentions: 6  
    113. COPD and lung cancer incidence in the Women's Health Initiative Observational Study: A brief report. Lung Cancer. 2020 03; 141:78-81. Nagasaka M, Lehman A, Chlebowski R, Haynes BM, Ho G, Patel M, Sakoda LC, Schwartz AG, Simon MS, Cote ML. PMID: 31958598; PMCID: PMC8898572.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    114. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. Int J Mol Sci. 2019 Dec 29; 21(1). Khan HY, Ge J, Nagasaka M, Aboukameel A, Mpilla G, Muqbil I, Szlaczky M, Chaker M, Baloglu E, Landesman Y, Mohammad RM, Azmi AS, Sukari A. PMID: 31905765; PMCID: PMC6982268.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    115. Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. Clin Lymphoma Myeloma Leuk. 2020 05; 20(5):305-311. Bumma N, Nagasaka M, Hemingway G, Miyashita H, Chowdhury T, Kim S, Vankayala HM, Ahmed S, Jasti P. PMID: 32144026.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    116. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review. Crit Rev Oncol Hematol. 2020 Jan; 145:102841. Nagasaka M, Sexton R, Alhasan R, Rahman S, Azmi AS, Sukari A. PMID: 31884204.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    117. Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids. J Neurol Neurosurg Psychiatry. 2020 03; 91(3):321-323. Yamauchi J, Sato T, Yagishita N, Araya N, Hasegawa D, Tsutsumi S, Nagasaka M, Coler-Reilly A, Inoue E, Takata A, Hasegawa Y, Yamano Y. PMID: 31662348.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    118. Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. Orphanet J Rare Dis. 2019 10 21; 14(1):227. Tsutsumi S, Sato T, Yagishita N, Yamauchi J, Araya N, Hasegawa D, Nagasaka M, Coler-Reilly ALG, Inoue E, Takata A, Yamano Y. PMID: 31639014; PMCID: PMC6802124.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    119. Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response? Oral Oncol. 2020 02; 101:104435. Sukari A, Nagasaka M. PMID: 31635973.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    120. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):247-254. Xia H, Xue X, Ding H, Ou Q, Wu X, Nagasaka M, Shao YW, Hu X, Ou SI. PMID: 31761448.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    121. A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors. Lung Cancer (Auckl). 2019; 10:95-105. Nagasaka M, Abdallah N, Crosby M, Thummala N, Patel D, Wozniak AJ, Gadgeel S, Abrams J, Sukari A. PMID: 31572037; PMCID: PMC6750163.
      View in: PubMed   Mentions: 2  
    122. Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. Front Microbiol. 2019; 10:2110. Tamaki K, Sato T, Tsugawa J, Fujioka S, Yagishita N, Araya N, Yamauchi J, Coler-Reilly ALG, Nagasaka M, Hasegawa Y, Yamano Y, Tsuboi Y. PMID: 31572323; PMCID: PMC6749079.
      View in: PubMed   Mentions: 10  
    123. Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report. Oral Oncol. 2019 12; 99:104350. Abdallah N, Nagasaka M, Chowdhury T, Raval K, Hotaling J, Sukari A. PMID: 31277904.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    124. Neuregulin 1 Fusion-Positive NSCLC. J Thorac Oncol. 2019 08; 14(8):1354-1359. Nagasaka M, Ou SI. PMID: 31128291.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    125. Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients. Clin Otolaryngol. 2019 07; 44(4):639-643. Sukari A, Nagasaka M, Diab M, Al Sibai K, Atassi B, Elayoubi JA, Kim S, Küçük Ö. PMID: 30784192; PMCID: PMC6844146.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    126. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. Anticancer Res. 2019 Feb; 39(2):781-790. Sukari A, Nagasaka M, Alhasan R, Patel D, Wozniak A, Ramchandren R, Vaishampayan U, Weise A, Flaherty L, Jang H, Kim S, Gadgeel S. PMID: 30711957; PMCID: PMC6886239.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    127. Unleash the power of the mighty T cells-basis of adoptive cellular therapy. Crit Rev Oncol Hematol. 2019 Apr; 136:1-12. Sukari A, Abdallah N, Nagasaka M. PMID: 30878123.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    128. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Lung Cancer (Auckl). 2018; 9:85-90. Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A. PMID: 30498383; PMCID: PMC6207227.
      View in: PubMed   Mentions: 17  
    129. Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. Front Microbiol. 2018; 9:1651. Sato T, Yagishita N, Tamaki K, Inoue E, Hasegawa D, Nagasaka M, Suzuki H, Araya N, Coler-Reilly A, Hasegawa Y, Tsuboi Y, Takata A, Yamano Y. PMID: 30090093; PMCID: PMC6068401.
      View in: PubMed   Mentions: 28  
    130. The allure of 'ALUR'. Ann Oncol. 2018 06 01; 29(6):1344-1346. Nagasaka M, Zhu VW, Ou SI. PMID: 29688274.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    131. Is this really just "fatigue"? A case series of immune-related central adrenal insufficiency secondary to immune checkpoint inhibitors. Clin Case Rep. 2018 Jul; 6(7):1278-1281. Nagasaka M, Abdallah N, Samantray J, Sukari A. PMID: 29988586; PMCID: PMC6028360.
      View in: PubMed   Mentions: 5  
    132. Liquid Biopsy to Identify Actionable Genomic Alterations. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:978-997. Ou SI, Nagasaka M, Zhu VW. PMID: 30231331; PMCID: PMC6865813.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    133. Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. Oral Oncol. 2018 05; 80:100-102. Sukari A, Nagasaka M, Abdallah N. PMID: 29605290.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    134. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther. 2018 01; 18(1):63-70. Nagasaka M, Gadgeel SM. PMID: 29168933; PMCID: PMC6863145.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansPHPublic Health
    135. EGFR-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing. J Natl Compr Canc Netw. 2017 10; 15(10):1188-1192. Sukari A, Nagasaka M, Wakeling E. PMID: 28982744.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    136. Retreatment With Osimertinib Following Pneumonitis. Clin Lung Cancer. 2018 01; 19(1):e53-e55. Nagasaka M, Gadgeel SM. PMID: 28736180.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    137. Histologic Transformation in NSCLC with PD-1 therapy. J Thorac Oncol. 2017 09; 12(9):e133-e134. Nagasaka M, Pansare RS, Abdulfatah E, Guan H, Tranchida P, Gadgeel SM. PMID: 28502723.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    138. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. Laryngoscope. 2017 10; 127(10):2260-2264. Nagasaka M, Zaki M, Issa M, Kim H, Abrams J, Sukari A. PMID: 28271529; PMCID: PMC6853181.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    139. Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site. Clin Genitourin Cancer. 2017 08; 15(4):e713-e717. Nagasaka M, Kukreja G, Abdulfatah E, Vaishampayan U, Sukari A. PMID: 28024951.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    140. PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report. J Immunother Cancer. 2016; 4:83. Nagasaka M, Zaki M, Kim H, Raza SN, Yoo G, Lin HS, Sukari A. PMID: 27895920; PMCID: PMC5109767.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    141. Cancer Immunology and Immunotherapy. Anticancer Res. 2016 11; 36(11):5593-5606. Sukari A, Nagasaka M, Al-Hadidi A, Lum LG. PMID: 27793882.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    142. Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer. Oncology (Williston Park). 2014 Jun; 28(6):526, 528, 530, 534. Saxena A, Nagasaka M, Li Z, Becker DJ, Levy BP. PMID: 25134330.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    143. Renal-protective effect of nondepressor dose of cicletanine in diabetic rats with hypertension. Am J Hypertens. 2000 Mar; 13(3):298-306. Kohzuki M, Wu XM, Kamimoto M, Yoshida K, Nagasaka M, Kanazawa M, Yasujima M, Saito T, Sato T. PMID: 10777035.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    144. Comparison of resting beta-methyl-iodophenyl pentadecanoic acid (BMIPP) and thallium-201 tomography using quantitative polar maps in patients with unstable angina. Jpn Circ J. 1997 Feb; 61(2):133-8. Suzuki A, Takada Y, Nagasaka M, Kato R, Watanabe T, Shimokata K, Yasui S. PMID: 9070968.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    145. Antley-Bixler syndrome: a disorder characterized by congenital synostosis of the elbow joint and the cranial suture. J Pediatr Orthop. 1996 Mar-Apr; 16(2):243-6. Kitoh H, Nogami H, Oki T, Arao K, Nagasaka M, Tanaka Y. PMID: 8742293.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    146. Allogeneic bone marrow transplantation in children: Tokai experience 1982 to 1984. Tokai J Exp Clin Med. 1985 Jun; 10(2-3):147-58. Kato S, Hoshi N, Nagasaka M, Muranaka S, Yabe H, Kimura M. PMID: 3010509.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    147. Phenotypic reversion of D+ and D- mutant clones in mouse myeloid leukemia. Kobe J Med Sci. 1983 Oct; 29(5):129-42. Maeda S, Chen HL, Nagasaka M, Sugiyama T. PMID: 6583460.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    148. Four cases of t(4;11) acute leukemia and its myelomonocytic nature in infants. Blood. 1983 Jun; 61(6):1174-81. Nagasaka M, Maeda S, Maeda H, Chen HL, Kita K, Mabuchi O, Misu H, Matsuo T, Sugiyama T. PMID: 6340755.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    149. Establishment and cytological characteristics of two in vitro T-cell lines derived from a child with acute lymphatic leukemia and a man with adult T-cell leukemia in Japan. Int J Cancer. 1982 Aug 15; 30(2):173-80. Nagasaka M, Maeda S, Mabuchi O, Takubo T, Nasu K, Wano Y, Sugiyama T. PMID: 6982237.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    150. QT duration and plasma electrolytes (Ca, Na, and K) in uremic patients. Jpn Heart J. 1972 May; 13(3):187-94. Nagasaka M, Yokosuka H, Yamanaka T, Sato T, Nakamura K. PMID: 4538251.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    151. CLINICAL FEATURE OF MYOCARDIAL INFARCTION IN JAPAN. Jpn Heart J. 1964 Nov; 5:497-511. YOSHITOSHI Y, HANAOKA W, NAGASAKA M, MIYASHITA H, YAMAGUCHI A, ITO T, WATANABE S, OSHIMA M, SHINOHARA Y. PMID: 14250894.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Misako's Networks
    Concepts (338)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (23)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCI Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California